Blood Pressure After Endovascular Stroke Therapy-II
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.
Also called NCT04116112
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Sponsor
- Registry
-
NCT04116112
-
- Other papers using this trial's data
- Blood Pressure Management After Endovascular Therapy for Acute Ischemic Stroke: The BEST-II Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT04116112. Randomized; single masking; primary purpose treatment. Start 2020-01-17 (actual); primary completion 2022-07-01 (actual). Results posted on 2023-10-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Blood Pressure After Endovascular Stroke Therapy-II
- Acronym
- BEST-II
- Condition
- Acute Stroke
- Condition
- Endovascular Thrombectomy
- Intervention (Drug)
- Nicardipine
- Intervention (Drug)
- Labetalol
- Intervention (Drug)
- Hydralazine
- Lead sponsor
- University of Cincinnati
- Collaborator
- National Institute of Neurological Disorders and Stroke (NINDS)
- Collaborator
- Vanderbilt University Medical Center
Record details
- Record id
cardio:ct-nct04116112- Content hash
4c075f37de528f179575efa9a3718a3bcd68846652f6a911fd8b74c56da427a8